Details of the Drug
General Information of Drug (ID: DMDQO0S)
| Drug Name |
BMS-753493
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Epofolate; Epothilone folate conjugate; BMS-493; BMS-748285 folate conjugate, Bristol-Myers Squibb; Targeted epothilone-folate conjugate (Endocyte technology, cancer), BMS; Targeted epothilone-folate conjugate (Endocyte technology, cancer), Bristol-Myers Squibb
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL is unavailable | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 5 | Molecular Weight (mw) | 1569.7 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | -2.7 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 38 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 16 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 32 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug ADMET Endpoint Profile (DAE)NEW | Click to Jump to the Detailed DAE Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Solid tumour/cancer | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | 2A00-2F9Z | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||
References


